Information Provided By:
Fly News Breaks for August 24, 2015
REGN
Aug 24, 2015 | 07:23 EDT
RBC Capital believes that investors' focus on Regeneron's anti-PCSK9 is probably misplaced, since the drug's usage will probably be constrained in any event and a longer duration competitor will probably take many years to materialize. Instead, the firm believes that investors should focus on Eylea and the company's 2015-2016 pipeline. RBC keeps a $665 price target and Outperform rating on Regeneron.
News For REGN From the Last 2 Days
There are no results for your query REGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.